InvestorsHub Logo
Followers 33
Posts 2432
Boards Moderated 0
Alias Born 03/02/2019

Re: None

Tuesday, 01/12/2021 12:07:30 AM

Tuesday, January 12, 2021 12:07:30 AM

Post# of 425944
While I think the consortium is a few basement dwellers...they did find this which I find interesting......

Deep-Under-Alert: Amarin has new hyper-triglyceride patent, Stockvadar-confirms, to go after generics AGAIN. Amarin claims a new novelty.

While past patents are currently set aside by the Arizona court, a new patent is not: "We have unexpectedly found that high purity eicosapentaenoic acid (EPA) is more susceptible to oxidative degradation than mixed omega-3-acid ethyl esters. In various embodiments, the invention provides pharmaceutical compositions comprising a fatty acid or a derivative thereof in a capsule shell that resists, hinders, attenuates, or prevents oxidation of the fatty acid or fatty acid derivative, for example to a greater extent than is provided by a standard type IIa capsule shell. In a related embodiment, the fatty acid comprises eicosapentaenoic acid (EPA) or a derivative of EPA, for example ethyl eicosapentaenoate (ethyl-EPA or E-EPA). In another embodiment, the fatty acid comprises ultra-pure EPA.

In one embodiment, the invention provides a pharmaceutical composition comprising ultra-pure EPA encapsulated in a capsule shell, where the ultra-pure EPA has a baseline peroxide value not greater than about 5 meq/mg and upon storage of the composition at 23° C. and 50% RH for a period of time, that ultra-pure EPA has a second peroxide value not greater than about 20 meq/mg.

In other embodiments, the invention provides a pharmaceutical composition comprising EPA (e.g. E-EPA or ultra-pure E-EPA) encapsulated in a capsule shell comprising a film forming material and a hygroscopic plasticizer, wherein the weight ratio of film-forming material to hygroscopic plasticizer is not less than about 2.5:1. Further, the capsule shell can optionally comprise a non-hygroscopic plasticizer. In one embodiment, the capsule contains no chemically modified gelatin, for example succinated or succinylated gelatin."

THIS IS A FRONT-LINE ASSAULT ON THE GENERIC!!! Having been granted, Amarin has new ground to sue Hikma/Reddy. The word is out: the generic version stinks--literally!!! It's an oxidation mess. ONLY Vascepa can be trusted.

https://www.freepatentsonline.com/10881632.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News